Women Veterans Face 67% Higher Risk of Inappropriate PTSD Prescriptions

by Staff Writer
September 16, 2024 at 8:15 AM UTC

Study finds female veterans 67% more likely to get non-recommended PTSD meds than males, revealing significant treatment gaps.

Clinical Relevance: Women don’t always have the same “textbook” symptoms of PTSD that men do.

  • Women veterans with PTSD are 67% more likely to receive non-recommended medications.
  • Despite guidelines, women are more frequently prescribed high-risk medications like benzodiazepines.
  • Clinicians should do more to understand gender-specific factors in PTSD treatment to improve safety and efficacy for women in the military.

A recent The Journal of Clinical Psychiatry study revealed that female veterans with post traumatic stress disorder (PTSD) are 67% more likely than male veterans to receive medications not on the recommended list for treating this condition.

Women veterans with PTSD are significantly more likely than veterans who are men to receive medications not recommended for their condition.

The findings reveal a significant and unexpected gap in the treatment of mental health issues between women and men in the military.

Exploring the Discrepancies

To understand prescribing patterns for PTSD more completely, Veterans Health Administration (VA) researchers examined one year’s worth of prescribing patterns from the VA data, looking at the records of over 800,000 veterans no longer on active duty, 12 percent of which were women. 

“In 2019, 15.8 percent of women veterans with PTSD were prescribed benzodiazepines compared to only 10.9 percent of men veterans with PTSD, despite guidelines recommending against their use due to both lack of evidence of effectiveness in treating PTSD and the risks outweighing the potential benefits,” the VA researchers wrote in their paper.

The discrepancy remained even after adjusting for various factors, including a bipolar disorder diagnosis, age, and previous psychiatric medication usage, they added.

Factors Influencing Prescriptions

There are several possible explanations for the substantial influence of gender on a provider’s prescribing decisions.

Healthcare providers can misinterpret women’s PTSD symptoms. Women don’t always experience PTSD the same way men do.

Additionally, the women in the study tended to be younger and were more likely to have a bipolar disorder diagnosis. They were also more likely to have multiple mental health issues compared to the men.

Earlier research supports the findings, regardless of the reasons.

For example, a Journal of General Internal Medicine review noted that women veterans saw a higher increase in SSRIs and SNRIs prescriptions than men over a 10 year period. The same study noted similar trends for atypical antipsychotics and non-benzodiazepine hypnotics.

Another recent study from the journal, Trauma Stress also found that women veterans with PTSD have historically been prescribed more psychiatric medications than men. They were more likely to receive medications like benzodiazepines and certain antidepressants over the decade the study’s data covered, despite guidelines advising against their use.

Insights and Takeaways

Of particular concern, the authors said, was the practice of off-label use to treat the women in the study.

When doctors prescribe a medication off-label, they believe it might help the patient even though the FDA hasn’t specifically approved it for that purpose.

Off-label prescribing is common in mental health care. However, the authors note that the study did not monitor the women carefully. They called for more oversight to ensure safety and effectiveness.

 “The call for greater scrutiny in off-label medication use is clear, advocating for better regulatory measures to safeguard against the potential adverse effects of such practices,” the JCP authors wrote. 

They stressed the need for tailored treatment strategies specifically designed for women in the military plus stricter guidelines to enhance the safety and efficacy of treatments. 

They also want to see further studies to fully understand the gender-specific factors influencing PTSD treatment. 

“To inform tailored intervention strategies, future work is needed to fully understand why women receive more medications recommended against use for PTSD,” the authors wrote.

Further Reading

FDA Rejects MDMA-Assisted PTSD Treatment

Assessing the Predictive Validity of Early Post-injury CAPS-5 for Later PTSD Diagnosis

The Long Road Toward Equitable MDMA Treatment in the United States

Original Research

Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study

During up to 4 years of treatment, the combination of olanzapine/samidorphan was safe and well-tolerated, and patients’ symptoms remained stable.

Jacob S. Ballon and others

Case Series

Combined Cyproheptadine and Dexamethasone Dependence: Is It Rare or Underreported? A Case Series

Three cases of cyproheptadine and dexamethasone dependence are presented, with individuals misusing the drugs for rapid weight and muscle gain.

Aniket Mukherjee and others